BridgeMD
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis
EU CTIS ID: 2023-506655-19-00
What this study is testing
To evaluate the efficacy of vixarelimab compared to placebo in the induction of clinical remission at Week 12
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosis of UC for at least 3 months
- Moderately to severely active UC, assessed by Modified Mayo Score (mMS)
- Inadequate response, loss of response to, or intolerance to conventional or advanced therapies for UC
You likely can't join if
- Diagnosis of Crohn’s disease or indeterminate colitis
- Suspicion of ischemic, radiation, microscopic, or infectious colitis
- Prior colectomy
- Inadequate response to or loss of response to previous treatment of UC with Janus kinase (JAK) inhibitors.
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
- Taiwan
- Mexico
- Argentina
- Brazil
- Korea, Republic of
- United States
- Israel
- Serbia
- Canada
- China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom; Taiwan; Mexico; Argentina; Brazil; Korea, Republic of and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.